Glucocorticoid Resistance is Associated with Poor Functional Outcome After Stroke

Anna Maria Lopatkiewicz1 · Elzbieta Gradek-Kwinta1 · Mateusz Czyzycki1 · Joanna Pera1 · Agnieszka Slowik1 · Tomasz Dziedzic1

Received: 22 November 2019 / Accepted: 18 February 2020 / Published online: 27 February 2020
© The Author(s) 2020

Abstract
Systemic inflammation is associated with poor outcome after stroke. Glucocorticoids (GCs) play a fundamental role in limiting inflammation. The aim of this study was to explore the associations between GC sensitivity, systemic inflammation, and outcome after ischemic stroke. The study population comprised 246 ischemic stroke patients (median age: 69.0 years; 41.1% female). To assess GC sensitivity, we incubated venous blood samples that were obtained at day 3 after stroke with lipopolysaccharide (10 ng/mL) and dexamethasone (10^-6 mol/L). We defined the GC sensitivity index as the ratio of tumor necrosis factor α (TNFα) released after blood stimulation with lipopolysaccharide and dexamethasone to the amount of TNFα released after blood stimulation with lipopolysaccharide alone. A higher index indicates higher GC resistance. The patients with poor functional outcome had a higher GC sensitivity index than those with good outcome (median: 16.1% vs. 13.5%, P < 0.01). In a logistic regression analysis adjusted for age, stroke severity, pneumonia, leukocyte count, plasma interleukin-6, and TNFα release ex vivo, a higher GC sensitivity index was associated with a higher risk of poor outcome after stroke (OR 2.32, 95% CI 1.21–4.45, P = 0.01). In conclusion, GC resistance is associated with poor functional outcome after stroke.

Keywords Stroke · Outcome · Inflammation · Glucocorticoid sensitivity

Background
Acute stroke is accompanied by both systemic inflammation and immunodepression (Chamorro et al. 2012; Murray et al. 2013). Systemic inflammation is reflected by an elevated level of circulating interleukin-6 (IL-6) and C-reactive protein (CRP) (Dziedzic 2015). Immunodepression manifests as a functional deactivation of monocytes, lymphopenia, and spleen atrophy (Chamorro et al. 2012). The laboratory hallmark of immunodepression is a reduction in tumor necrosis factor α (TNFα) release after blood stimulation ex vivo with endotoxin. Elevated levels of circulating IL-6 and CRP as well as reduced TNFα production ex vivo are associated with poor outcome after stroke (Chamorro et al. 2012; Dziedzic 2015; Klimiec et al. 2018).

Glucocorticoids (GCs) are an important element of the feedback mechanism in the immune system and restrain the immune response. A failure of GCs to inhibit the inflammatory reaction may contribute to disease development. The ultimate biological response to GCs is determined by the concentration of GCs and individual differences in GC sensitivity (Silverman and Sternberg 2012; Quax et al. 2013).

Multiple factors that act at the level of GC receptors and their signaling pathway can influence the response to GCs. Among them, inflammation may contribute to GC resistance (Pace et al. 2007; Pace and Miller 2009). Cytokines such as TNFα, IL-1, and IL-6 can decrease the expression of GC receptors, inhibit translocation of the GC receptors from the cytoplasm to the nucleus, and disrupt the protein–protein interactions of GC receptors and their binding to DNA. Moreover, cytokines can induce relatively inert receptor isoforms that exhibit reduced binding affinity.

Another way in which cytokines might contribute to GC resistance is the regulation of GC bioavailability. Pro-inflammatory cytokines tend to favor increased GC bioavailability by reducing levels of corticosteroid binding globulin (CBG) and multidrug-resistant P-glycoprotein (MDR). CBG binds to a majority of circulating cortisol and limits its activity because only unbound cortisol is...
able to diffuse across cell membranes and interact with GC receptors. MDR is an efflux pump that decreases the intracellular concentrations of GCs. In addition, cytokines can influence the expression of 11-β-hydroxysteroid dehydrogenase isoenzymes, which play an important role in the regulation of local concentrations of cortisol.

In animal studies, increased activity of GC-inducible kinase 1 exacerbated ischemic brain damage (Inoue et al. 2016). Moreover, the proteasome-dependent degradation of GC receptors contributes to GC insensitivity at the hypoxic blood–brain barrier (Kleinschnitz et al. 2011).

The aim of this study was to explore the associations between GC sensitivity, circulating IL-6 as a marker of systemic inflammation, and outcome after ischemic stroke. We hypothesized that GC resistance is associated with poor functional outcome after stroke.

Methods

Patient Selection and Clinical Assessment

The participants in this study were prospectively recruited from consecutive stroke patients who were hospitalized in the Department of Neurology, University Hospital, Krakow, Poland, between October 2016 and October 2018. The inclusion criteria were: (1) ischemic stroke; (2) time from the onset of stroke symptoms to admission < 24 h; (3) pre-stroke-modified Rankin Scale (mRS) score of 0–2 (independent of daily activities); (4) National Institute of Health Stroke Scale (NIHSS) score on admission > 3; and (5) informed patient consent. The exclusion criteria were: (1) chronic inflammatory, autoimmune, or cancerous diseases; and (2) the use of steroids or immunomodulatory drugs before stroke or in the acute phase of stroke. Written informed consent was obtained from each patient included in the study. The study protocol was approved by the Bioethics Committee of Jagiellonian University.

The neurological deficit on admission was assessed using the NIHSS, which quantifies stroke-related neurological deficit. Higher scores indicate greater impairment and more severe stroke (Lyden et al. 1994).

Functional outcome was assessed at 3 months after stroke using mRS which is a 7-grade scale used to measure the degree of disability. Scores of 0 to 2 indicate functional independence, scores of 3 to 5 indicate dependence of the patient in daily activities, and 6 indicates death (van Swieten et al. 1998). Unfavorable outcomes were defined as a mRS of 3 to 6.

Stroke etiology was determined using the TOAST criteria (Adams et al. 1993).

Laboratory Assays

Venous blood was collected in heparinized tubes (Sarstedt, Germany) at day 3 after stroke. To avoid diurnal variation, the blood was obtained between 7:00 and 7:30 AM. The whole blood was diluted by 1:5 in sterile RPMI 1640 medium supplemented with L-glutamine (Sigma-Aldrich, St. Louis, MO). The samples were then stimulated in sterile tubes (Lonza, Walkersville, MD) for 4 h at 37 °C in 5% CO2 with LPS (10 ng/mL, Escherichia coli 0111:B4, Sigma-Aldrich, St. Louis, MO) or LPS and dexamethasone-21-phosphate (10⁻⁶ mol/L, Sigma-Aldrich, St. Louis, MO). The supernatants were removed and stored at −80 °C until further analysis.

Similarly to previous studies, TNFα was chosen as an indicator of GC sensitivity because this cytokine has the greatest sensitivity to GCs in comparison to IL-1β and IL-6 (DeRijk et al. 1997).

The GC sensitivity index was defined as the ratio of TNFα released after blood stimulation with LPS and dexamethasone to the amount of TNFα released after blood stimulation with LPS alone. A higher index indicates lower GC sensitivity (and higher GC resistance).

TNFα and IL-6 concentrations were measured using a commercially available ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. The cytokine detection limits were 0.19 pg/mL for TNFα and 0.11 pg/mL for IL-6. For both cytokines, the intra-assay CVs were <5%, and the inter-assay CVs were <10%.

Statistical Analysis

The χ² test was used to compare proportions, while the Mann–Whitney U test and Kruskal–Wallis test were used to compare continuous variables between groups. Logistic regression was used to determine the predictors of functional outcome. Patients within the upper tertile of the GC sensitivity index were compared to the patients in other tertiles. The receiver operating characteristic curves were used to find an optimal cutoff level of GC sensitivity index that differentiates patients with good outcome from patients with poor outcome. The variables with P ≤ 0.05 in the univariate analysis were included in the multivariate analysis. The calculations were performed using the program STATISTICA for Windows (version 12.5, Statsoft, Poland).
Results

We initially included 255 patients (median age: 69.0 years; 41.4% female; median NIHSS: 10). However, information about outcome was not available for 9 patients. Thus, the final cohort included 246 patients (median age: 69.0 years; 41.1% female; median NIHSS: 9).

The baseline characteristics of the included patients categorized by tertiles of the GC sensitivity index are shown in Table 1.

The NIHSS score, white blood cell (WBC) count, rate of pneumonia, and plasma level of IL-6 increased across the tertiles of the GC sensitivity index whereas the TNFα release ex vivo decreased. The frequency of poor outcome was the lowest in patients in the lower tertile and the highest in patients in the upper tertile of the GC sensitivity index.

The baseline characteristic of patients with good outcome and patients with poor outcome are shown in Table 2.

The patients with poor outcome were older, had more severe neurological deficit on admission, and more frequently suffered from in-hospital pneumonia. Compared to the patients with good outcome, the patients with poor outcome had higher plasma IL-6 levels and lower TNFα release after blood stimulation with LPS.

The GC index was higher in patients with poor outcome. The GC index correlated with plasma IL-6 levels ($R = 0.21$, $P < 0.05$) and TNFα release ex vivo ($R = -0.16$, $P < 0.05$).

The odds ratio (OR) for the highest tertile versus the other tertiles of the GC index was 3.56 (95% CI 2.04–6.21, $P < 0.01$) for poor functional outcome. Other predictors of poor outcome were: age (OR 1.04, 95% CI 1.02–1.06, $P < 0.01$), NIHSS score (OR 1.11, 95% CI 1.07–1.16, $P < 0.01$), pneumonia (OR 10.59, 95% CI 1.29–86.92, $P = 0.03$), WBC count (OR 1.31, 95% CI 1.17–1.46, $P < 0.01$), plasma IL-6 (OR 1.04, 95% CI 1.02–1.06, $P < 0.01$) and TNFα release ex vivo (OR 0.73, 95% CI 0.59–0.89, $P < 0.01$). After adjusting for age, NIHSS score, pneumonia, WBC count, plasma IL-6, and TNFα release, the OR for poor functional outcome was 2.32 (95% CI 1.21–4.45, $P = 0.01$).

In the whole group of patients, a GC index above 13.7% was associated with poor outcome both the univariate analysis (OR 3.53, 95% CI 2.02–6.16, $P < 0.01$) and the multivariate analysis adjusted for age, NIHSS score, pneumonia, WBC count, plasma IL-6, and TNFα release.

Table 1 The baseline characteristics of patients categorized by tertiles of the GC index

| Statistically significant $P$ values are highlighted in bold |
|---|---|---|---|---|
| Age, median (IQs) | Lower tertile (N=81) | Middle tertile (N=82) | Upper tertile (N=83) | $P$ value |
| Female, n (%) | 33 (40.7) | 31 (37.8) | 37 (44.6) | 0.67 |
| Hypertension, n (%) | 59 (72.8) | 68 (82.9) | 66 (79.5) | 0.28 |
| Diabetes mellitus, n (%) | 26 (32.1) | 19 (23.2) | 23 (27.7) | 0.44 |
| Atrial fibrillation, n (%) | 22 (27.2) | 26 (31.7) | 23 (27.7) | 0.78 |
| Myocardial infarction, n (%) | 8 (9.9) | 10 (12.2) | 15 (18.1) | 0.29 |
| Previous stroke or transient ischemic attack, n (%) | 8 (9.9) | 8 (9.8) | 13 (15.7) | 0.41 |
| NIHSS score on admission, n (%) | 7 (4–16) | 8.5 (5–16) | 13 (6–18) | $< 0.01$ |
| Stroke etiology | | | | 0.17 |
| Large vessel disease, n (%) | 21 (25.9) | 20 (24.4) | 24 (28.9) | |
| Small vessel disease, n (%) | 5 (6.2) | 7 (8.5) | 1 (1.2) | |
| Cardio-embolic, n (%) | 21 (25.9) | 30 (36.6) | 22 (26.5) | |
| Other, n (%) | 29 (35.8) | 24 (29.3) | 34 (41.0) | |
| Undermined, n (%) | 5 (6.2) | 1 (1.2) | 2 (2.4) | |
| In-hospital pneumonia, n (%) | 0 (0) | 1 (1.2) | 8 (9.6) | $< 0.01$ |
| Intravenous thrombolysis, n (%) | 47 (58.0) | 46 (56.1) | 45 (54.2) | 0.89 |
| Mechanical thrombectomy, n (%) | 24 (29.6) | 22 (26.8) | 19 (22.9) | 0.62 |
| White blood cells count $\times 10^3$ µL, median (IQs) | 7.7 (6.5–9.3) | 8.1 (6.5–9.9) | 9.3 (7.7–11.4) | $< 0.01$ |
| Serum IL-6 (pg/mL), median (IQs) | 3.5 (1.8–8.0) | 4.9 (2.3–10.9) | 6.9 (3.1–21.1) | $< 0.01$ |
| Ex vivo TNFα release after LPS stimulation (pg/mL), median (IQs) | 2689 (1903–3826) | 2268 (1725–3451) | 2060 (1517–2792) | 0.04 |
| Poor outcome, n (%) | 24 (29.6) | 32 (39.0) | 54 (65.1) | $< 0.01$ |

GC glucocorticoid, IQ interquartile, NIHSS National Institute of Health Stroke Scale
WBC count, plasma IL-6, and TNFα release (OR 2.16, 95% CI 1.15–4.05, \(P = 0.02\)).

The results of one study suggested that diabetic patients might have blunted GC sensitivity to stress (Carvalho et al. 2015). After the exclusion of diabetic patients, the GC sensitivity index remained an independent predictor of poor outcome in the multivariate analysis (OR 2.55, 95% CI 1.19–5.46, \(P = 0.01\)).

Discussion

We found that GC resistance was associated with poor functional outcome after stroke. This association was independent of not only age and stroke severity, which are the most important stroke prognosticators, but also from circulating IL-6, a marker of systemic inflammation, and ex vivo release of TNFα, a marker of immunodepression (Chamorro et al. 2012). To the best of our knowledge, this is the first study to investigate the relationship between GC resistance and outcome in stroke patients.

Our study revealed an association between GC sensitivity, circulating IL-6 and, to a lesser degree, TNFα synthesized ex vivo. The plasma level of IL-6 increased with the tertiles of the GC sensitivity index, whereas TNFα release ex vivo decreased. There are several hypothetical possibilities regarding the relationship between GC resistance, systemic inflammation, and post-stroke immunodepression. First, circulating cytokines including IL-6 could trigger GC resistance (Pace et al. 2007; Pace and Miller 2009). Second, GC resistance could lead to systemic inflammation by inadequate control of the immune reaction by GCs. Third, excessive GC release after cerebral ischemia might contribute to immunodepression (Mracsko et al. 2014). Fourth, since plasma IL-6 levels, TNF release ex vivo, and GC resistance depend on stroke severity, one common biological mechanism induced by brain injury could be responsible for all these phenomena.

The exact biological pathways leading to GC resistance in patients with poor outcome remain unknown. GC sensitivity is modulated by numerous genetic and acquired factor, including inflammatory mediators. Further studies are needed to explore the potential mechanisms of GC resistance in acute stroke. Better insight into the pathogenesis of GC resistance in stroke patients might be obtained through measurements of diurnal cortisol release, cortisol bioavailability, the expression of GC receptors in different populations of blood cells, GC receptor affinity, and GC receptor post-translational modification.

### Table 2
The baseline characteristics of patients with good outcome and patients with poor outcome 3 months after stroke

|                        | Good outcome (\(N = 136\)) | Poor outcome (\(N = 110\)) | \(P\) value |
|------------------------|-----------------------------|-----------------------------|-------------|
| Age, median (IQs)      | 66 (58–75.5)                | 72 (63–81)                  | \(<0.01\)   |
| Female, n (%)          | 52 (38.2)                   | 49 (48.5)                   | 0.32        |
| Hypertension, n (%)    | 103 (75.7)                  | 90 (81.8)                   | 0.25        |
| Diabetes mellitus, n (%) | 34 (25.0)               | 34 (30.9)                   | 0.30        |
| Atrial fibrillation, n (%) | 40 (29.4)              | 31 (28.2)                   | 0.83        |
| Myocardial infarction, n (%) | 17 (12.5)              | 16 (14.5)                   | 0.64        |
| Previous stroke or transient ischemic attack, n (%) | 13 (9.6)               | 16 (14.5)                   | 0.23        |
| NIHSS score on admission, n (%) | 6.5 (4–13)            | 14.5 (7–19)                  | \(<0.01\)   |
| Stroke etiology        |                            |                             | 0.14        |
| Large vessel disease, n (%) | 28 (20.6)               | 37 (33.6)                   |             |
| Small vessel disease, n (%) | 9 (6.6)               | 4 (3.6)                     |             |
| Cardio-embolic, n (%)  | 44 (32.3)                   | 29 (26.4)                   |             |
| Other, n (%)           | 6 (4.4)                     | 2 (1.8)                     |             |
| Undermined, n (%)      | 49 (36.0)                   | 38 (34.5)                   |             |
| In-hospital pneumonia, n (%) | 1 (0.7)                | 8 (7.3)                    | \(<0.01\)   |
| Intravenous thrombolysis, n (%) | 77 (56.6)             | 61 (55.4)                   | 0.85        |
| Mechanical thrombectomy, n (%) | 39 (28.7)              | 26 (40.0)                   | 0.37        |
| White blood cells count, \(\times 10^3/\mu L\), median (IQs) | 7.7 (6.5–9.0) | 9.5 (7.7–11.9) | \(<0.01\) |
| Serum IL-6 (pg/mL), median (IQs) | 3.2 (1.8–6.4) | 8.7 (4.6–24.3) | \(<0.01\) |
| Ex vivo TNFα release after LPS stimulation (pg/mL), median (IQs) | 2607 (1774–3809) | 2089 (1517–2835) | \(<0.01\) |
| GC sensitivity index (%), median (IQs) | 13.5 (11.4–16.0) | 16.1 (13.7–19.7) | \(<0.01\) |

Statistically significant \(P\) values are highlighted in bold

GC glucocorticoid, IQ interquartile, NIHSS National Institute of Health Stroke Scale
GCs regulate many physiological processes beyond the immune system. They can exert a modulatory effect on a variety of brain functions, including neurotransmission and neuronal plasticity (Gray et al. 2017). Thus, GC resistance might have a negative impact on stroke outcome independently from impaired counter-regulatory control of the immune response. An example of GC action beyond the immune system is the stabilization of the blood–brain barrier and the mitigation of cerebral edema. Kleinschnitz et al. (2011) showed GC insensitivity at the level of the blood–brain barrier in mice subjected to cerebral ischemia.

Pharmacological modulation of GC sensitivity could be considered as a potential strategy to improve stroke outcome. GC resistance is largely caused by the de-activation of histone deacetylase 2 (HDAC2), which is critical for the activity of GC receptors that mediate the anti-inflammatory effect (Barnes 2011). Selective activation of HDAC2 can be achieved with theophylline, which restores HDAC2 activity in macrophages and reverses GC resistance (Cosio et al. 2004). Further studies are needed to determine whether the pharmacological modulation of GC sensitivity in addition to reperfusion therapy is beneficial in stroke.

Our work has several limitations. We measured the GC index only once and used only one dose of dexamethasone to assess GC sensitivity. We took blood samples at day 3 after stroke rather than upon admission. However, this minimized the diurnal variation in cytokine production related to the time of blood collection. Furthermore, it allowed us to grasp the effect of systemic inflammation because the blood IL-6 level rises between 6 and 72 h after the onset of stroke symptoms (Pusch et al. 2015). Finally, our observational study is unable to demonstrate a causal relationship between GC resistance and stroke outcome.

Conclusions

GC resistance is associated with poor functional outcome after stroke. These novel clinical observations might be important for future experimental studies exploring the relationship between GCs, inflammation, and stroke prognosis.

Acknowledgement This study was supported by the Grant from National Science Center (2015/19/B/NZ4/00287).

Author Contributions AML and TD prepared study protocol. AML, EGK and MC collected the data. TD supervised the study. AML and TD wrote the manuscript. JP and AS revised the manuscript for intellectual content. All authors read and approved the final manuscript.

Funding This study was supported by the Grant from National Science Center (2015/19/B/NZ4/00287).

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no competing interests.

Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Bioethics Committee of Jagiellonian University, opinion number: 122.6120.249.2016) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24:35–41

Barnes PJ (2011) Glucocorticosteroids: current and future directions. Br J Pharmacol 163:29–43

Carvalho LA, Urbanova L, Hamer M, Hackett RA, Lazzarino AI, Steptoe A (2015) Blunted glucocorticoid and mineralocorticoid sensitivity to stress in people with diabetes. Psychoneuroendocrinology 51:209–218

Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R (2012) The immunology of acute stroke. Nat Rev Neurol 8:401–410

Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689–695

DeRijk R, Michelson D, Karp B, Petrides J, Gallivern E, Deuster P, Piacotti G, Gold PW, Sternberg EM (1997) Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. J Clin Endocrinol Metab 82:2182–2191

Dziedzic T (2015) Systemic inflammation as a therapeutic target in acute ischemic stroke. Expert Rev Neurother 15:523–531

Gray JD, Kogan JF, Marrocco J, McEwen B (2017) Genomic and epigenomic mechanisms of glucocorticoids in the brain. Nat Rev Endocrinol 13:661–673

Inoue K, Leng T, Yang T, Zeng Z, Ueki T, Xiong ZG (2016) Role of serum- and glucocorticoid-inducible kinases in stroke. J Neurochem 138:354–361
Kleinschnitz C, Blecharz K, Kahles T, Schwarz T, Kraft P, Göbel K, Meuth SG, Burek M, Thum T, Stoll G, Förster C (2011) Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome. Stroke 42:1081–1089
Klimiec E, Kowalska K, Pasinska P, Pera J, Slowik A, Dziedzic T (2018) Reduced release of TNFα and IP-10 after ex vivo blood stimulation with endotoxin is associated with poor outcome after stroke. Cytokine 102:51–54
Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J (1994) Improved reliability of the NIH Stroke Scale using video training NINDS TPA Stroke Study Group. Stroke 25:2220–2226
Mracsko E, Liesz A, Karcher S, Zorn M, Bari F, Veltkamp R (2014) Differential effects of sympathetic nervous system and hypothalamic-pituitary-adrenal axis on systemic immune cells after severe experimental stroke. Brain Behav Immun 41:200–209
Murray KN, Bugghey HF, Denes A, Allan SM (2013) Systemic immune activation shapes stroke outcome. Mol Cell Neurosci 53:14–25
Pace TW, Miller AH (2009) Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 1179:86–105
Pace TW, Hu F, Miller AH (2007) Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 21:9–19
Pusch G, Debrabant B, Molnar T, Feher G, Papp V, Banati M, Kovacs N, Szapary L, Illes Z (2015) Early dynamics of P-selectin and interleukin 6 predicts outcomes in ischemic stroke. J Stroke Cerebrovasc Dis 24:1938–1947
Quax RA, Manenshijn L, Koper JW, Hazes JM, Lamberts SW, van Rossum EF, Feelders RA (2013) Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol 9:670–686
Silverman MN, Sternberg EM (2012) Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci 1261:55–63
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.